Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short term Debt: 2019-2025

Historic Short term Debt for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $702,184.

  • China SXT Pharmaceuticals' Short term Debt fell 99.94% to $4,475 in Q3 2025 from the same period last year, while for Sep 2025 it was $4,475, marking a year-over-year decrease of 99.94%. This contributed to the annual value of $702,184 for FY2025, which is 42.42% up from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Short term Debt is $702,184, which was up 42.42% from $493,054 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Short term Debt registered a high of $12.1 million during FY2021, and its lowest value of $11,404 during FY2022.
  • Moreover, its 3-year median value for Short term Debt was $493,054 (2024), whereas its average is $454,230.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Short term Debt tumbled by 99.91% in 2022 and then soared by 1,368.37% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Short term Debt (Yearly) stood at $12.1 million in 2021, then slumped by 99.91% to $11,404 in 2022, then surged by 1,368.37% to $167,453 in 2023, then skyrocketed by 194.44% to $493,054 in 2024, then soared by 42.42% to $702,184 in 2025.